Last reviewed · How we verify
NCT05724992: PROPH-ITA
Familial Pancreatic Cancer PROPHilation Program in Italy
NA trial testing Saliva swab testing in Candidates for Hereditary Pancreatic Cancer Testing in 3,000 participants. Currently enrolling.
20 December 2027
Quick facts
| Lead sponsor | Associazione Italiana per lo Studio del Pancreas |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 3,000 |
| Start date | 20 December 2022 |
| Primary completion | 20 December 2027 |
| Estimated completion | 20 December 2028 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Saliva swab testing
Conditions studied
- Candidates for Hereditary Pancreatic Cancer Testing — all drugs for Candidates for Hereditary Pancreatic Cancer Testing →
Sponsor
Associazione Italiana per lo Studio del Pancreas — full company profile →
Who can join
Adults 18 to 80, any sex, with Candidates for Hereditary Pancreatic Cancer Testing. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only. Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test. Up to 3,000 participants will be enrolled in this study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer.
Paiella S, Secchettin E, Archibugi L, De Luca R, et al · · 2026 · cited 1× · PMID 41691430 · DOI 10.1002/ueg2.70187
Verify or expand the search:
- PubMed search for NCT05724992
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Candidates for Hereditary Pancreatic Cancer Testing
Currently open trials in the same condition.
- NCT03762590 — GENetic Education Risk Assessment and TEsting Study · NA · active not recruiting
Other Associazione Italiana per lo Studio del Pancreas trials
Trials by the same sponsor.
- NCT05733130 — Italian Registry Chronic Pancreatitis · recruiting
- NCT04793932 — Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL) · Phase 3 · active not recruiting
- NCT04095195 — Registry of Subjects at Risk of Pancreatic Cancer · recruiting
- NCT06381362 — Italian Registry of Minimally Invasive Pancreatic Surgery · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05724992 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Associazione Italiana per lo Studio del Pancreas
- Last refreshed: 15 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05724992.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing